Pfizer Inc.
NYSE:PFEDrug Manufacturers - General
-$0.71 today
- Market cap
- $159.94B
- Beta
- 0.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.32
- Dividend yield
- 6.82%
Volume 37.37M
Average 36.66M
PFE Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Pfizer Inc.NYSE: PFE
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin narrows to 23.5%
Operating margin was 23.5% in Q2 FY2026, down 2.2 pp from a year earlier. On a trailing-twelve-month basis it was 26.7%, up 0.6 pp year over year. Over 3 fiscal years it narrowed by 9.9 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 18 analysts of 39.2% for the fiscal year ending Dec 2026, up from 27.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 23.5%-6.0 pp QoQ
- Last fiscal yearDec 2025
- 27.8%+4.3 pp YoY
- LTMJun 2026
- 26.7%+0.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2.2 pp | +4.8 pp | +6.9 pp |
| 1 year | +4.3 pp | +11.4 pp | +7.1 pp |
| 3 years | -9.9 pp | +9.6 pp | +19.4 pp |
| 5 years | +7.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 27.8%
- Year-over-year change
- +4.3pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.8% | +4.3pp |
| FY2024 | 2024-12-31 | 23.5% | +16.1pp |
| FY2023 | 2023-12-31 | 7.4% | -30.3pp |
| FY2022 | 2022-12-31 | 37.7% | +12.8pp |
| FY2021 | 2021-12-31 | 24.9% | — |
Operating Margin vs competitors
How PFE compares with its peers on the latest reported figures
- PFE's LTM Jun 2026 operating margin of 26.7% is the 5th highest of the 11 companies compared; the peer median is 24.7%.
- Its year-over-year change of +0.6 pp is the 6th highest of 11, against a peer median of +1.0 pp.
- Over three fiscal years its change of -9.9 pp compares with a peer median of +7.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 49.7% | +7.6 pp | +15.2 pp | |
| LTM Sep 2026 | 35.5% | +20.4 pp | +1.6 pp | |
| LTM Jun 2026 | 30.5% | +0.3 pp | +12.9 pp | |
| LTM Jun 2026 | 28.1% | +7.3 pp | +8.8 pp | |
| LTM Jun 2026 | 26.7% | +0.6 pp | -9.9 pp | |
| LTM Sep 2026 | 25.7% | -0.4 pp | +0.9 pp | |
| LTM Sep 2026 | 23.7% | +1.6 pp | +14.9 pp | |
| LTM Jun 2026 | 20.7% | +4.5 pp | +3.6 pp | |
| LTM Jun 2026 | 16.7% | -16.9 pp | +5.3 pp | |
| LTM Jun 2026 | 14.8% | -3.6 pp | -4.5 pp | |
| LTM Jun 2026 | -4.9% | -32.8 pp | +12.9 pp | |
| Peer median (excluding PFE) | 24.7% | +1.0 pp | +7.0 pp | |
Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 81.29B | 101.18B | 59.55B | 63.63B | 62.58B |
| Cost of Revenue | 30.82B | 34.34B | 24.95B | 17.85B | 16.07B |
| Gross Profit | 50.47B | 66.83B | 34.6B | 45.78B | 46.51B |
| Gross Margin | 62.1% | 66.1% | 58.1% | 71.9% | 74.3% |
| Research & Development | 13.83B | 11.43B | 10.68B | 10.82B | 10.44B |
| Selling, General & Admin | 12.7B | 13.68B | 14.77B | 14.73B | 13.79B |
| Operating Expenses | 30.23B | 28.71B | 30.18B | 30.84B | 29.11B |
| Depreciation & Amortization | 5.19B | 5.06B | 6.29B | 7.01B | 6.59B |
| EBITDA | 30.79B | 41.03B | 9.56B | 18.13B | 16.78B |
| EBITDA Margin | 37.9% | 40.6% | 16.0% | 28.5% | 26.8% |
| Operating Income | 20.24B | 38.12B | 4.42B | 14.94B | 17.41B |
| Operating Margin | 24.9% | 37.7% | 7.4% | 23.5% | 27.8% |
| Interest Income | 36M | 251M | 1.62B | 545M | 603M |
| Interest Expense | 1.29B | 1.24B | 2.21B | 3.09B | 2.67B |
| Other Income / Expenses | 4.08B | (3.39B) | (3.36B) | (6.92B) | (9.89B) |
| Income Before Tax | 24.31B | 34.73B | 1.06B | 8.02B | 7.52B |
| Pre-Tax Margin | 29.9% | 34.3% | 1.8% | 12.6% | 12.0% |
| Income Tax Expense | 1.85B | 3.33B | (1.12B) | (28M) | (266M) |
| Net Income | 21.98B | 31.37B | 2.12B | 8.03B | 7.77B |
| Net Margin | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
| EPS (Basic) | 3.95 | 5.59 | 0.38 | 1.42 | 1.36 |
| EPS (Diluted) | 3.88 | 5.47 | 0.37 | 1.41 | 1.36 |
| Weighted Avg Shares | 5.6B | 5.61B | 5.64B | 5.66B | 5.68B |
| Weighted Avg Shares (Diluted) | 5.71B | 5.73B | 5.71B | 5.7B | 5.69B |
Pfizer Inc.
NYSE:PFE
Intrinsic Alpha fair value
Locked
Current Price
$28.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.